Zyngenia's founding management team also includes Joseph Amprey, M.D., Ph.D., former head of MedImmune Ventures, Inc., as Chief Business Officer. Dr. Amprey joined MedImmune Ventures as the first full-time employee and helped grow the portfolio from 13 investments to 28. He led 11 deals during his time at MedImmune Ventures and served on five boards. Recently, David Hilbert, Ph.D., has been appointed the Vice President and Head of Research and Development. Dr. Hilbert formerly served as Vice President of Research at both Cellective Therapeutics and Human Genome Sciences. Dr Hilbert led Research and Development at Cellective until its acquisition by MedImmune in 2005. At Human Genome Sciences, Dr Hilbert led the transformation of the company from a genomics research company to an integrated drug development organization. His expertise in oncology, autoimmunity and antibody development enabled the first IND for the company and was pivotal in the development of ABthrax and Benlysta.
In conjunction with the Series A financing, David M. Mott, NEA General Partner, will become Chairman of the Board. Robert Garland, M.D., Partner at NEA, will also join the company's board of directors. Mr. Mott focuses on biopharmaceutical investments at NEA. He is Chairman of 3-V Biosciences, a Director of Ardelyx and Zosano Pharma, and serves on the advisory board of the Scripps Translational Science Institute. Prior to joining NEA, he was President and CEO of MedImmune, which was acquired by AstraZeneca for $15.6 billion in 20
|SOURCE Zyngenia, Inc.|
Copyright©2009 PR Newswire.
All rights reserved